HOME > Investor Relations > Financial Results Highlights > New Drug Pipeline

New Drug Pipeline

New Drug Development

Taisho Pharmaceutical has positioned the four therapeutic areas of infectious diseases, orthopedic disorders, central nervous system, and metabolic diseases as its priority fields for research and development (R&D). In each of these fields, Taisho Pharmaceutical aims to discover innovative drugs that will pave the way for future growth.

Priority fields (infectious diseases/orthopedic disorders/CNS diseases/metabolic diseases)

In Japan, TS-152 for the planned indication of rheumatoid arthritis has entered Phase 3, while TS-091 for the planned indication of central disorders of hypersomnolence has entered Phase 2. Apart from these, Phase 2 clinical trials are underway in Japan for examining the efficacy of the TS-141 against infantile attention-deficit hyperactivity disorder (ADHD), the TS-133 against alopecia and the TS-142 against insomnia. Outside Japan, drugs mainly in the domain of psychiatric disorders, such as the TS-121 and the TS-134, are being developed. To create a number of new drugs chiefly in key domains amid intensifying competition for new drug creation, we work with outside research institutes and with domestic and overseas businesses to carry out research and development in an effort to enrich the pipeline (or the lineup of developed products).

New Drug Pipeline

As of Aug 1, 2018

In Japan

Filed for Application
Name Target disease Development with
Taurine powder 98% "Taisho"
(Oral)
Prevention of recurrence of stroke-like episodes for MELAS*
※Additional indication
In-house
Phase3
Name Application Development with
TS-152**
(Injection)
Rheumatoid arthritis In-license
Phase2
Name Application Development with
TS-091
(Oral)
Central disorders of hypersomnolence In-house
TS-141
(Oral)
Childhood Attention-Deficit/Hyperactivity Disorder In-house
TS-133
(Topical)
Alopecia In-house
TS-142
(Oral)
Insomnia In-house


Overseas

Phase2
Name Target disease Development with
TS-121
(Oral)
Depression In-house
Phase1
Name Target disease Development with
TS-071***
(Oral)
Type 2 diabetes In-house
TS-091
(Oral)
Central disorders of hypersomnolence In-house
TS-134
(Oral)
Schizophrenia In-house

*MELAS:Mitochondrial myopathy, Encephalopathy, Lactic Acidosis and Stroke-like episodes
**TS-152: Generic name:Ozoralizumab
***TS-071: Generic name:Luseogliflozin Hydrate  In Japan: Product name: Lusefi